FIELD: biotechnology.
SUBSTANCE: invention relates to the biotechnology. Described is a composition for respiratory delivery, obtained and effective for treating and/or preventing infection of influenza virus in a mammal, containing two or more influenza virus-neutralizing monoclonal antibodies in the form of a single dose and in an effective amount of 0.005 mg/kg to 1 mg/kg and a suitable pharmaceutically acceptable carrier, diluent or excipient, where at least a first antibody is directed against influenza virus A of one subtype, and at least a second antibody is directed against influenza A virus of another subtype than said first antibody, or against influenza virus B, or there are at least two second antibodies, one of which is directed against influenza A virus of said other subtype and the other antibody is directed against influenza B virus. Described is a method of treating or preventing influenza virus in a mammal using said composition. Presented is a preventive and therapeutic combination comprising: a first composition prepared for intranasal or inhalation administration, containing two or more influenza virus-neutralizing monoclonal antibodies in the form of a single dose of 0.005 mg/kg to 1 mg/kg against influenza viruses having different specificity, and a second composition prepared for intraperitoneal or intravenous administration, containing one or more influenza antibodies in the form of a single dose of 1 mg/kg to 10 mg/kg, where one or more antibodies in the second composition are the same as one or more antibodies in the first composition, or other antibodies. Disclosed is a method for reducing transmission of influenza virus, involving administering said composition intranasally or inhalation to a subject exposed, at risk of exposure to influenza virus or exhibiting clinical signs of infection with influenza virus.
EFFECT: invention extends the range of products for treating and preventing influenza.
37 cl, 38 dwg, 2 tbl, 11 ex
Title | Year | Author | Number |
---|---|---|---|
ANTIBODIES SUITABLE FOR PASSIVE IMMUNIZATION AGAINST INFLUENZA, AND COMPOSITIONS THEREOF, COMBINATIONS AND METHODS OF USING | 2015 |
|
RU2720282C1 |
ANTIBODIES USED PASSIVE VACCINATION AGAINST INFLUENZA | 2012 |
|
RU2668802C2 |
H7N9 INFLUENZA A THERAPY | 2015 |
|
RU2682049C2 |
ANTIBODIES SUITABLE FOR PASSIVE IMMUNIZATION AGAINST INFLUENZA | 2011 |
|
RU2635999C2 |
NEUTRALISING ANTI-INFLUENZA A ANTIBODIES AND USES THEREOF | 2014 |
|
RU2683498C2 |
VACCINES AND METHODS OF TREATING CANINE INFLUENZA | 2006 |
|
RU2396976C2 |
NEUTRALIZING ANTIBODIES AGAINST THE INFLUENZA A VIRUS AND WAYS OF THEIR APPLICATION | 2014 |
|
RU2803850C2 |
NEUTRALIZING BINDING MOLECULES DIRECTED AGAINST INFLUENZA VIRUS, AND METHODS OF THEIR APPLICATION | 2016 |
|
RU2721706C2 |
FUNCTIONAL INFLUENZA VIRUS-LIKE PARTICLES (VLPs) | 2006 |
|
RU2483751C2 |
NEUTRALISING ANTI-INFLUENZA A VIRUS ANTIBODIES AND USING THEM | 2009 |
|
RU2553325C2 |
Authors
Dates
2019-09-30—Published
2014-03-14—Filed